The Effect of Placebo Adherence on Reducing Cardiovascular Mortality: a Meta-analysis

Overview

Journal Clin Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 2013 Nov 23

PMID 24264475

Citations 10

Authors

Zhao Yue

Cheng Cai

Yang Ai-Fang

Tang Feng-Min

Chen Li

Wang Bin

Affiliations

Soon will be listed here.

Abstract

Objective: We aim to demonstrate the effect of placebo adherence on reducing CV mortality.

Backgrounds: Good adherence, whether to drug or placebo treatment, is associated with lower CV mortality. However, current evidence for the positive effect of placebo adherence on reducing CV mortality is relatively weak.

Methods: We conducted a fixed-effect meta-analysis of eight randomized clinical trials to evaluate the effect of placebo adherence on reducing CV mortality. We made a comparison between good placebo adherence and poor drug adherence.

Results: Compared with poor adherence to drug treatment, good adherence to placebo treatment was associated with lower CV mortality (OR = 0.68, 95% CI 0.60-0.77).

Conclusion: Good adherence to placebo has a positive effect on reducing CV mortality. The effect of adherence on reducing CV mortality may be independent of the drug effect.

Citing Articles

Is It All in Your Head? Placebo Effects in Concussion Prevention.

Smoliga J, Bleakley C, Pearce A Sports Med. 2025; .

PMID: 39777706 DOI: 10.1007/s40279-024-02158-2.

Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features.

Wilkins C, Hamman H, Hamman J, Steenekamp J Pharmaceutics. 2024; 16(2).

PMID: 38399239 PMC: 10892518. DOI: 10.3390/pharmaceutics16020178.

Risk Factors Control After an Acute Coronary Syndrome and Association with Major Adverse Cardiovascular Events: A Single Center Experience in Latin-America.

Ruiz-Beltran A, Alcaraz-Guzman A, Campos-Franco D, Jimenez-Lopez C, Ruiz-Beltran S, Delgadillo-Rodriguez H High Blood Press Cardiovasc Prev. 2023; 30(2):183-189.

PMID: 36735221 DOI: 10.1007/s40292-023-00560-x.

Placebo: a brief updated review.

Pardo-Cabello A, Manzano-Gamero V, Puche-Canas E Naunyn Schmiedebergs Arch Pharmacol. 2022; 395(11):1343-1356.

PMID: 35943515 PMC: 9361274. DOI: 10.1007/s00210-022-02280-w.

Methylphenidate augmentation of escitalopram to enhance adherence to antidepressant treatment: a pilot randomized controlled trial.

Paulus M, Kuplicki R, Victor T, Yeh H, Khalsa S BMC Psychiatry. 2021; 21(1):582.

PMID: 34798853 PMC: 8603485. DOI: 10.1186/s12888-021-03583-7.

References

Walenta K, Sinning J, Werner C, Bohm M . Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. Clin Res Cardiol. 2011; 100(11):955-71. DOI: 10.1007/s00392-011-0370-8. View

Stilley C, Sereika S, Muldoon M, Ryan C, Dunbar-Jacob J . Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med. 2004; 27(2):117-24. DOI: 10.1207/s15324796abm2702_6. View

Blaschke T, Osterberg L, Vrijens B, Urquhart J . Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2011; 52:275-301. DOI: 10.1146/annurev-pharmtox-011711-113247. View

Gitt A, Junger C, Jannowitz C, Karmann B, Senges J, Bestehorn K . Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry). Clin Res Cardiol. 2010; 100(4):277-87. DOI: 10.1007/s00392-010-0240-9. View

Rasmussen J, Chong A, Alter D . Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297(2):177-86. DOI: 10.1001/jama.297.2.177. View

. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J. 1997; 18(11):1718-24. DOI: 10.1093/oxfordjournals.eurheartj.a015165. View

Avorn J, Monette J, Lacour A, Bohn R, Monane M, Mogun H . Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998; 279(18):1458-62. DOI: 10.1001/jama.279.18.1458. View

Padula A, Pressman A, Vittinghoff E, Grady D, Neuhaus J, Ackerson L . Placebo adherence and mortality in the Heart and Estrogen/Progestin Replacement Study. Am J Med. 2012; 125(8):804-10. PMC: 3423204. DOI: 10.1016/j.amjmed.2012.02.014. View

Irvine J, Baker B, Smith J, Jandciu S, Paquette M, Cairns J . Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom Med. 1999; 61(4):566-75. DOI: 10.1097/00006842-199907000-00023. View

10.

Gallagher E, Viscoli C, Horwitz R . The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA. 1993; 270(6):742-4. View

11.

Bohm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T . Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J. 2013; 166(2):306-314.e7. DOI: 10.1016/j.ahj.2013.04.016. View

12.

Laufs U, Rettig-Ewen V, Bohm M . Strategies to improve drug adherence. Eur Heart J. 2010; 32(3):264-8. DOI: 10.1093/eurheartj/ehq297. View

13.

Lara Fernandes J, Serrano Jr C, Toledo F, Hunziker M, Zamperini A, Teo F . Acute and chronic effects of exercise on inflammatory markers and B-type natriuretic peptide in patients with coronary artery disease. Clin Res Cardiol. 2010; 100(1):77-84. DOI: 10.1007/s00392-010-0215-x. View

14.

Andersohn F, Willich S . The healthy adherer effect. Arch Intern Med. 2009; 169(17):1635-6. DOI: 10.1001/archinternmed.2009.324. View

15.

Horwitz R, Viscoli C, Berkman L, Donaldson R, Horwitz S, Murray C . Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990; 336(8714):542-5. DOI: 10.1016/0140-6736(90)92095-y. View

16.

Herrler T, Bohm M, Heeschen C . More good reasons for adherence to statin therapy during acute coronary syndromes. Eur Heart J. 2008; 29(17):2061-3. DOI: 10.1093/eurheartj/ehn348. View

17.

Ho P, Bryson C, Rumsfeld J . Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009; 119(23):3028-35. DOI: 10.1161/CIRCULATIONAHA.108.768986. View

18.

Friedmann E, Brooks M, Thomas S, Haakenson C, Morris M, Wimbush F . Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). Ann Epidemiol. 1996; 6(2):93-101. DOI: 10.1016/1047-2797(95)00134-4. View

19.

Pressman A, Avins A, Neuhaus J, Ackerson L, Rudd P . Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST). Contemp Clin Trials. 2012; 33(3):492-8. PMC: 3312975. DOI: 10.1016/j.cct.2011.12.003. View

20.

Jespersen L, Abildstrom S, Hvelplund A, Prescott E . Persistent angina: highly prevalent and associated with long-term anxiety, depression, low physical functioning, and quality of life in stable angina pectoris. Clin Res Cardiol. 2013; 102(8):571-81. DOI: 10.1007/s00392-013-0568-z. View